Heparin cofactor II: a simple assay method and results of its clinical application.

Thromb Res

Blood Coagulation Laboratory, Linz, Austria.

Published: October 1987

A simple assay method of heparin cofactor II (HC II) activity is described. The procedure is based on the following principle: Antithrombin III (AT III) in plasma is inactivated by addition of an IgG fraction of goat serum after immunization of the animals against human AT III. Complete inactivation of AT III could be shown by absence of an anti Xa-effect of heparinized plasma treated with this antibody. Thrombin was only partially inhibited after inactivation of AT III. The characteristics of this inhibition were typical for the action of HC II. This method was applied for an assay of HC II activity. After optimizing of the method practical application in clinical routine screening was carried out. A diminution of HC II was observed in liver cirrhosis and in DIC but not in AT III deficiency. In 15 out of 269 cases of recurrent DVT there were HC II activities below 70% of normal. In 4 out of these patients activities of HC II were repeatedly between 44% and 52%. In arterial obstructive disease there was an HC II activity of less than 60% in 18 out of 583 patients and in 11 of them the HC II levels were repeatedly between 45% and 54%.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0049-3848(87)90411-7DOI Listing

Publication Analysis

Top Keywords

heparin cofactor
8
simple assay
8
assay method
8
inactivation iii
8
iii
6
cofactor simple
4
method
4
method clinical
4
clinical application
4
application simple
4

Similar Publications

Heparin resistance (HR) in patients on extracorporeal membrane oxygenation (ECMO) exacerbates bleeding and thrombogenesis. Thus far, there is no universal definition of what this condition entails and no unified strategy for assessing heparin's efficacy in ECMO patients. The most frequent discrepancy when it comes to defining HR is the difference in the reported doses: units per day (U/d) or per kilogram per hour (U/kg/h).

View Article and Find Full Text PDF

Proteomics Analysis of Five Potential Plasma-derived Exosomal Biomarkers for Acute Myocardial Infarction.

Curr Med Chem

January 2025

Department of Cardiology, Taizhou Hospital of Zhejiang Province, affiliated to Wenzhou Medical University, Linhai, Zhejiang Province, China.

Aims: This study was to explore the relationship between plasma exosomes and Acute myocardial infarction (AMI).

Background: Acute myocardial infarction (AMI) is one of the most common cardiovascular complications. Recent studies have shown that exosomes play a crucial role in the development and progression of cardiovascular diseases.

View Article and Find Full Text PDF

Post-Translational Modifications Control Phase Transitions of Tau.

ACS Cent Sci

November 2024

Department of Chemistry, University of Colorado, Boulder, Boulder, Colorado 80309, United States.

Article Synopsis
  • * Researchers synthesized a Tau segment with various PTMs and observed that these modifications generally hinder Tau's assembly into PHFs, with acetylation showing variable effects, and phosphorylation consistently reducing aggregation.
  • * The findings emphasize that PTMs located outside the rigid core of Tau filaments are crucial for initiating PHF formation, illustrating the complex role of these modifications in influencing Tau aggregation dynamics.
View Article and Find Full Text PDF

A collaborative study to establish the second national standard for antithrombin concentrate in Korea.

Biologicals

February 2025

Blood Products Division, Biopharmaceuticals & Herbal Medicine Evaluation Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju-si, South Korea. Electronic address:

This study aimed to establish a second national standard for antithrombin (AT) concentrate that can be used for potency assays of AT products. A collaborative study was conducted involving four laboratories, including national control laboratories and manufacturers in Korea, and the suitability of a candidate material to serve as the second national standard for AT concentrate was evaluated. The candidate material was manufactured using a process approved for Good Manufacturing Practices.

View Article and Find Full Text PDF

Structural analysis of the stable form of fibroblast growth factor 2 - FGF2-STAB.

J Struct Biol X

December 2024

Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.

Fibroblast growth factor 2 (FGF2) is a signaling protein that plays a significant role in tissue development and repair. FGF2 binds to fibroblast growth factor receptors (FGFRs) alongside its co-factor heparin, which protects FGF2 from degradation. The binding between FGF2 and FGFRs induces intracellular signaling pathways such as RAS-MAPK, PI3K-AKT, and STAT.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!